Research programme: small molecule therapeutics - Rafael Pharmaceuticals

Drug Profile

Research programme: small molecule therapeutics - Rafael Pharmaceuticals

Alternative Names: CPI 1826; CPI 3220; CPI 618; CPI-3514; CPI-3517

Latest Information Update: 12 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cornerstone Pharmaceuticals
  • Developer Rafael Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Haematological disorders

Most Recent Events

  • 12 Jun 2017 Preclinical development is ongoing for Cancer in USA (Rafael Pharmaceuticals pipeline, June 2017)
  • 12 Jun 2017 Preclinical trials in Haematological disorders in USA (PO) before June 2017 (Rafael Pharmaceuticals pipeline, June 2017)
  • 05 Jun 2017 Cornerstone Pharmaceuticals is now called Rafael Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top